NEMO stands for: Treatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide.
NEMO is an EU FP7 funded project that will be the largest multicentered European study of neonatal seizures and their treatment.
The aim of the NEMO study is to develop an effective antiepileptic drug regimen suitable for treatment of seizures in newborn babies using innovative strategies targeted specifically to the needs and peculiarities of babies.
In the first instance, NEMO study will evaluate bumetanide, a drug targeted at an age dependent mechanism which is thought to be responsible for the high incidence of seizure in the neonatal period. This will be the first time that an antiepileptic drug (AED) specifically aimed at this age-group will be evaluated in a large, adequately powered, randomised trial with EEG monitoring, recognised to be the “gold standard” method for seizure diagnosis in the newborn. Bumetanide cannot be tested as an AED on older children or adults as this mechanism ceases to be effective during the first few months of life.